US5962490A
(en)
|
1987-09-25 |
1999-10-05 |
Texas Biotechnology Corporation |
Thienyl-, furyl- and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
|
US5736509A
(en)
*
|
1990-12-14 |
1998-04-07 |
Texas Biotechnology Corporation |
Cyclic peptide surface feature mimics of endothelin
|
AU4376893A
(en)
*
|
1992-05-19 |
1993-12-13 |
Immunopharmaceutics, Inc. |
Compounds that modulate endothelin activity
|
US5352800A
(en)
*
|
1993-03-11 |
1994-10-04 |
Merck & Co., Inc. |
Process for the production of a novel endothelin antagonist
|
US5374638A
(en)
*
|
1993-03-19 |
1994-12-20 |
Merck & Co., Inc. |
Six membered ring fused imidazoles substituted with phenoxyphenylacetic acid derivatives used to treat asthma
|
US5401745A
(en)
*
|
1993-03-19 |
1995-03-28 |
Merck & Co., Inc. |
Quinazolinones substituted with phenoxyphenylacetic acid derivatives
|
US5334598A
(en)
*
|
1993-03-19 |
1994-08-02 |
Merck & Co., Inc. |
Six-membered ring fused imidazoles substituted with phenoxyphenylacetic acid derivatives
|
US5420133A
(en)
*
|
1993-03-19 |
1995-05-30 |
Merck & Co., Inc. |
Quinazolinones substituted with phenoxyphenylacetic acid derivatives
|
US5767310A
(en)
*
|
1993-03-19 |
1998-06-16 |
Merck & Co., Inc. |
Phenoxyphenylacetic acid derivatives
|
US5527890A
(en)
*
|
1993-04-16 |
1996-06-18 |
Glycomed Incorporated |
Derivatives of triterpenoid acids and uses thereof
|
EP0626174A3
(en)
*
|
1993-04-21 |
1996-01-03 |
Takeda Chemical Industries Ltd |
Method and composition for the prophylaxis and / or treatment of underactive organs.
|
US6541498B2
(en)
|
1993-05-20 |
2003-04-01 |
Texas Biotechnology |
Benzenesulfonamides and the use thereof to modulate the activity of endothelin
|
US6376523B1
(en)
|
1994-05-20 |
2002-04-23 |
Texas Biotechnology Corporation |
Benzenesulfonamides and the use thereof to modulate the activity of endothelin
|
US6613804B2
(en)
|
1993-05-20 |
2003-09-02 |
Encysive Pharmaceuticals, Inc. |
Biphenylsulfonamides and derivatives thereof that modulate the activity of endothelin
|
US6342610B2
(en)
|
1993-05-20 |
2002-01-29 |
Texas Biotechnology Corp. |
N-aryl thienyl-, furyl-, and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
|
US6030991A
(en)
*
|
1993-05-20 |
2000-02-29 |
Texas Biotechnology Corp. |
Benzenesulfonamides and the use thereof to modulate the activity of endothelin
|
ATE165811T1
(de)
*
|
1993-06-11 |
1998-05-15 |
Shionogi & Co |
Zwischenprodukte für die herstellung von endothelinrezeptor-antagonist-triterpen-derivat n
|
US5686478A
(en)
*
|
1993-07-20 |
1997-11-11 |
Merck & Co. Inc. |
Endothelin antagonists
|
CN1034334C
(zh)
*
|
1993-08-14 |
1997-03-26 |
贵州省中医研究所 |
齐酞酸钠及其药物组合物
|
US5492917A
(en)
*
|
1993-09-29 |
1996-02-20 |
Merck & Co., Inc. |
Endothelin antagonists incorporating a cyclobutane
|
US5559135A
(en)
*
|
1994-09-14 |
1996-09-24 |
Merck & Co., Inc. |
Endothelin antagonists bearing pyridyl amides
|
US5538991A
(en)
*
|
1994-09-14 |
1996-07-23 |
Merck & Co., Inc. |
Endothelin antagonists bearing 5-membered heterocyclic amides
|
US5945448A
(en)
*
|
1995-06-02 |
1999-08-31 |
Shionogi & Co., Ltd. |
Brain edema inhibitor
|
US5977117A
(en)
|
1996-01-05 |
1999-11-02 |
Texas Biotechnology Corporation |
Substituted phenyl compounds and derivatives thereof that modulate the activity of endothelin
|
US5958905A
(en)
|
1996-03-26 |
1999-09-28 |
Texas Biotechnology Corporation |
Phosphoramidates, phosphinic amides and related compounds and the use thereof to modulate the activity of endothelin
|
US5804585A
(en)
*
|
1996-04-15 |
1998-09-08 |
Texas Biotechnology Corporation |
Thieno-pyridine sulfonamides derivatives thereof and related compounds that modulate the activity of endothelin
|
US5783705A
(en)
|
1997-04-28 |
1998-07-21 |
Texas Biotechnology Corporation |
Process of preparing alkali metal salys of hydrophobic sulfonamides
|
US6432994B1
(en)
|
1997-04-28 |
2002-08-13 |
Texas Biotechnology Corporation |
Sulfonamides for treatment of endothelin-mediated disorders
|
US6326507B1
(en)
|
1998-06-19 |
2001-12-04 |
Trustees Of Dartmouth College |
Therapeutic compounds and methods of use
|
US7566452B1
(en)
|
1999-05-04 |
2009-07-28 |
New York University |
Cancer treatment with endothelin receptor antagonists
|
PL197782B1
(pl)
|
1999-12-31 |
2008-04-30 |
Encysive Pharmaceuticals Inc |
Sulfonoamidy, środek farmaceutyczny i zastosowanie sulfonoamidów
|
AU2003221074A1
(en)
*
|
2002-03-22 |
2003-10-08 |
Shionogi And Co., Ltd. |
Process for producing triterpene derivative
|
US20050175667A1
(en)
*
|
2004-02-10 |
2005-08-11 |
Wenda Carlyle |
Use of endothelin antagonists to prevent restenosis
|
EP1757573A4
(en)
|
2004-05-14 |
2008-05-07 |
Shionogi & Co |
Oxidation reaction of alcohol with hydrogen peroxide and tungsten catalyst
|
JP5225686B2
(ja)
*
|
2004-12-21 |
2013-07-03 |
ダウ グローバル テクノロジーズ エルエルシー |
ポリプロピレンをベースとした接着剤組成物
|
US20070207989A1
(en)
*
|
2006-03-03 |
2007-09-06 |
Savipu Pharmaceuticals |
Diterpene derivatives for the treatment of cardiovascular, cancer and inflammatory diseases
|
WO2007103727A2
(en)
*
|
2006-03-03 |
2007-09-13 |
Savipu Pharmaceuticals |
Triterpene derivatives for the treatment of cancer and inflammatory disease by inhibition of nf-kb
|
US7323476B2
(en)
*
|
2006-03-03 |
2008-01-29 |
Savipu Pharmaceuticals |
Myriceric acid derivatives for the treatment of cancer, cardiovascular and inflammatory diseases
|
MX2008011844A
(es)
*
|
2006-03-13 |
2008-10-02 |
Encysive Pharmaceuticals Inc |
Formulaciones de sitaxsentano de sodio.
|
MX2008011842A
(es)
*
|
2006-03-13 |
2008-10-02 |
Encysive Pharmaceuticals Inc |
Procedimientos y composiciones para el tratamiento de insuficiencia cardiaca diastolica.
|
US20070243273A1
(en)
*
|
2006-04-12 |
2007-10-18 |
Savipu Pharmaceuticals |
Reduction of the Deleterious Effects of Tobacco Smoking
|
US20080026061A1
(en)
*
|
2006-06-22 |
2008-01-31 |
Reichwein John F |
Crystalline N-(4-chloro-3-methyl-5-isoxazolyl)-2-[2-methyl-4.5-(methylenedioxy)phenylacetyl]-thiophene-3-sulfonamide
|
US20080017207A1
(en)
*
|
2006-07-18 |
2008-01-24 |
Savipu Pharmaceuticals |
Reduction of the Deleterious Effects of Tobacco Smoking by the Induction of Phase 2 Enzymes by Nerf2
|
US20080187608A1
(en)
*
|
2007-02-05 |
2008-08-07 |
Savipu Pharmaceuticals |
Enriched fractions from clary sage for the treatment of cancer, cardiovascular and inflammatory diseases
|
US20090022821A1
(en)
*
|
2007-07-17 |
2009-01-22 |
Inderjit Kumar Dev |
Compositions from wax myrtle for the treatment of cancer, cardiovascular and inflammatory diseases
|
CA2711834C
(en)
|
2008-01-11 |
2017-03-14 |
Reata Pharmaceuticals, Inc. |
Synthetic triterpenoids and methods of use in the treatment of disease
|
US7915402B2
(en)
|
2008-04-18 |
2011-03-29 |
Reata Pharmaceuticals, Inc. |
Antioxidant inflammation modulators: oleanolic acid derivatives with saturation in the C-ring
|
CN103342729B
(zh)
*
|
2013-03-26 |
2016-09-14 |
中国科学院上海药物研究所 |
咖啡酰基取代的五环三萜类衍生物及其用途
|
MX2019005401A
(es)
|
2016-11-08 |
2019-08-05 |
Reata Pharmaceuticals Inc |
Metodos para tratar el sindrome de alport con bardoxolona metilo o analogos de la misma.
|
SG11202003668YA
(en)
|
2018-01-04 |
2020-05-28 |
Amryt Res Limited |
Betulin-containing birch bark extracts and their formulation
|